Zacks Investment Research upgraded shares of Beyondspring (NASDAQ:BYSI) from a hold rating to a buy rating in a research note released on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $21.00 price target on the stock.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

A number of other equities research analysts also recently weighed in on BYSI. HC Wainwright reaffirmed a buy rating and set a $41.00 price target on shares of Beyondspring in a research note on Wednesday, September 18th. ValuEngine raised Beyondspring from a hold rating to a buy rating in a research note on Wednesday, October 2nd.

BYSI opened at $17.00 on Wednesday. Beyondspring has a fifty-two week low of $13.06 and a fifty-two week high of $25.79. The business has a 50-day moving average of $18.37 and a 200-day moving average of $17.41. The company has a market capitalization of $391.73 million, a PE ratio of -7.02 and a beta of 1.30.

Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings results on Wednesday, September 18th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.05). Equities analysts forecast that Beyondspring will post -1.54 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Beyondspring during the 2nd quarter valued at about $11,904,000. Vanguard Group Inc. acquired a new position in shares of Beyondspring during the 2nd quarter valued at about $956,000. Northern Trust Corp acquired a new position in shares of Beyondspring during the 2nd quarter valued at about $720,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Beyondspring during the 2nd quarter valued at about $528,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Beyondspring during the 2nd quarter valued at about $516,000. 5.27% of the stock is currently owned by institutional investors and hedge funds.

Beyondspring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Featured Article: Basic Economics creates winners and losers

Get a free copy of the Zacks research report on Beyondspring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.